welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
Healthcare Providers

Ronald Cohn, MD, FACMG

Healthcare Provider
President and CEO
The Hospital for Sick Children
555 University Avenue
Toronto, Canada

Ronald Cohn joined The Hospital for Sick Children as the Chief of the Division of Clinical and Metabolic Genetics, Co-Director of the Centre for Genetic Medicine and Senior Scientist in September 2012. On July 1st, 2016  he was appointed to the position of Chief of Paediatrics, The Hospital for Sick Children and Chair of Paediatrics at The University of Toronto”. Dr. Ronald Cohn is serving as President and CEO of The Hospital for Sick Children since May 1, 2019.

He received his medical degree from the University of Essen, Germany.  After his postdoctoral fellowship at the Howard Hughes Medical Institute in the laboratory of Dr. Kevin Campbell, he moved to Baltimore where he was the first combined resident in paediatrics and genetics at the Johns Hopkins University.

Dr. Ronald Cohn research Interests include maintenance of muscle mass in inherited and acquired muscle disorders, molecular mechanisms of muscle regeneration and fibrosis, hypotonia with a particular focus on muscle and connective tissue disorders and translating next generation sequencing into daily clinical diagnostics and management.

His laboratory is currently for the first time applying knowledge of normal mechanisms of muscle protection in the hibernating mammal to the disease process of disuse muscle atrophy in non-hibernating mammals. This will provide unique insights into the fundamental cellular and molecular pathways underlying skeletal muscle atrophy and the protection against it.


Representative Publications:

Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy

Exon Snipping in Duchenne Muscular Dystrophy

Duchenne muscular dystrophy: Ringo to the rescue?

Disruption of the beta-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E

Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy